FY2022 · ended Dec 31, 2022 · Revenue $8.09M, -40.6% YoY · Filed Mar 13, 2024
Solid Biosciences Inc. (SLDB) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$157.4 million. As of Sep 30, 2026 it held $348.9 million in cash and investments and $19.6 million in total debt.
Revenue
$8.09M
-40.6% vs prior year
Net income
$-174.32M
-39.8% vs prior year
Operating cash flow (TTM)
$-198.92M
-50.3% vs year-ago TTM
Free cash flow (TTM)
$-200.30M
-50.4% vs year-ago TTM
EPS
$-1.99
+35.0% vs prior year
Dividend per share
None
Shares outstanding
98.39M
+27.0% vs prior year
Net cash
$329.30M
as of Sep 30, 2026
Operating margin
-1315.2%
FY 2022
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SLDB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Charlestown, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1707502
- Former names
- Solid Biosciences, LLC (until Jan 25, 2018)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $8.1M | $13.6M |
| Operating income | -$179.2M | -$129.7M | -$104.3M | -$106.5M | -$72.3M |
| Net income | -$174.3M | -$124.7M | -$96.0M | -$86.0M | -$72.2M |
| Diluted EPS | -$1.99 | -$3.06 | -$4.83 | -$10.10 | — |
| Operating cash flow | -$156.3M | -$100.0M | -$94.2M | -$98.0M | -$77.8M |
| Free cash flow | -$157.4M | -$100.7M | -$95.7M | -$101.0M | -$79.0M |
| Total assets | $232.5M | $188.7M | $164.9M | $260.3M | $232.4M |
| Total liabilities | $52.5M | $51.4M | $38.5M | $48.6M | $24.2M |
| Stockholders' equity | $180.0M | $137.2M | $126.5M | $211.7M | $208.2M |
| Cash and investments | $187.8M | $148.9M | $123.6M | $213.7M | $207.8M |
| Total debt | $21.2M | $24.2M | $26.3M | $26.2M | $2.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Other events
|
Aug 6, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 10, 2026 | Jun 10, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| ARS | Annual report to shareholders | Apr 23, 2026 | Dec 31, 2025 |
All 737 Solid Biosciences Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.